S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME

Hanna, R., Frangoul, H., Mckinney, C., Pineiro, L., Mapara, M., Chang, K.-H., Jaskolka, M., Kim, K., Rizk, M., Afonja, O., Lawal, A., & Walters, M. (2023). S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME. HemaSphere, 7(S3), e05170e0. https://doi.org/10.1097/01.hs9.0000967968.05170.e0

Authors:

Rabi Hanna

Haydar Frangoul

Christopher Mckinney

Luis Piñeiro

Markus Y. Mapara

Kai‐Hsin Chang

Michael C. Jaskolka

Keunpyo Kim

Maha Rizk

Olubunmi Afonja

Adebayo Lawal